These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 25017008)
21. A Novel Risk Stratification-Based Immunomodulatory Treatment Strategy for Vogt-Koyanagi-Harada Disease. Jin K; Liang A; Song H; Xiao F; Gao F; Han X; Zhang M; Zhao C Am J Ophthalmol; 2024 Jun; 262():25-33. PubMed ID: 38369223 [TBL] [Abstract][Full Text] [Related]
22. Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings. Vasconcelos-Santos DV; Sohn EH; Sadda S; Rao NA Retina; 2010 Jan; 30(1):33-41. PubMed ID: 20010321 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography. Fan S; Lin D; Hu J; Cao J; Wu K; Li Y; Liu R; Dai ML; Bao Z; Wang Y Eye (Lond); 2021 Jul; 35(7):1993-1998. PubMed ID: 33024324 [TBL] [Abstract][Full Text] [Related]
24. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases. Usui Y; Goto H; Sakai J; Takeuchi M; Usui M; Rao NA Graefes Arch Clin Exp Ophthalmol; 2009 Aug; 247(8):1127-32. PubMed ID: 19308440 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic Value of Optical Coherence Tomography in the Early Diagnosis of Macular Complications in Chronic Vogt-Koyanagi-Harada Disease. Agarwal M; Radosavljevic A; Patnaik G; Rishi E; Pichi F Ocul Immunol Inflamm; 2022 May; 30(4):801-808. PubMed ID: 33136534 [TBL] [Abstract][Full Text] [Related]
27. Spectral domain optical coherence tomography and autofluorescence in a case of acute posterior multifocal placoid pigment epitheliopathy mimicking Vogt-Koyanagi-Harada disease: case report and review of literature. Lee GE; Lee BW; Rao NA; Fawzi AA Ocul Immunol Inflamm; 2011 Feb; 19(1):42-7. PubMed ID: 21034311 [TBL] [Abstract][Full Text] [Related]
28. Relationship between retinal lesions and inward choroidal bulging in Vogt-Koyanagi-Harada disease. Hosoda Y; Uji A; Hangai M; Morooka S; Nishijima K; Yoshimura N Am J Ophthalmol; 2014 May; 157(5):1056-63. PubMed ID: 24491415 [TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618 [TBL] [Abstract][Full Text] [Related]
30. RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy. Hashizume K; Imamura Y; Fujiwara T; Machida S; Ishida M; Kurosaka D Retina; 2016 Feb; 36(2):415-21. PubMed ID: 26352553 [TBL] [Abstract][Full Text] [Related]
31. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: Prevention of late autoimmune complications by early intervention. Abu El-Asrar AM; Al Rashed FA; AlBloushi AF; Tobaigy MF; Gikandi PW; Herbort CP; Opdenakker G Acta Ophthalmol; 2023 Mar; 101(2):e236-e245. PubMed ID: 36128841 [TBL] [Abstract][Full Text] [Related]
34. Changes of choroidal structure after corticosteroid treatment in eyes with Vogt-Koyanagi-Harada disease. Egawa M; Mitamura Y; Akaiwa K; Semba K; Kinoshita T; Uchino E; Sonoda S; Sakamoto T Br J Ophthalmol; 2016 Dec; 100(12):1646-1650. PubMed ID: 26906951 [TBL] [Abstract][Full Text] [Related]
35. Acquired myopia in Vogt-Koyanagi-Harada disease. Takahashi H; Takase H; Terada Y; Mochizuki M; Ohno-Matsui K Int Ophthalmol; 2019 Mar; 39(3):521-531. PubMed ID: 29397539 [TBL] [Abstract][Full Text] [Related]
36. Vogt-Koyanagi-Harada disease: recurrence rates after initial-onset disease differ according to treatment modality and geographic area. Herbort CP; Tugal-Tutkun I; Khairallah M; Abu El Asrar AM; Pavésio CE; Soheilian M Int Ophthalmol; 2020 Sep; 40(9):2423-2433. PubMed ID: 32418076 [TBL] [Abstract][Full Text] [Related]
37. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Keino H; Goto H; Mori H; Iwasaki T; Usui M Am J Ophthalmol; 2006 Jun; 141(6):1140-1142. PubMed ID: 16765691 [TBL] [Abstract][Full Text] [Related]